Skip to main content

Tasmanian Devil Cancer Immunotherapy

Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

WIKIMEDIA, KERESHScientists working to slow the spread of a deadly facial cancer through populations of the Tasmania’s iconic marsupial Sarcophilus harrisii, or the Tasmanian devil, have announced progress by injecting live cancer cells into individuals with the disease. The study, which reports that some golf-ball-size tumors disappeared entirely after the injections, was published Thursday (March 9) in Scientific Reports.

“When we saw those tumors get smaller it was so exciting,” University of Tasmania immunologist Greg Woods told BBC News. “This is almost a eureka moment for us because it's the first time we can say for sure that it was the immunotherapy that was making the tumor shrink.”

The team of researchers, which included scientists from the United Kingdom and Denmark, administered devil facial tumor disease (DFTD) cells to six animals with the cancer. The cells, which expressed the surface major histocompatibility complex (MHC)-I molecule typically missing from DFTD tumors, allowed immune cells to infiltrate and shrink the cancerous growths. “We used the cancer cells, cultured them in a laboratory, and made them express genes that made them become visible to the devils' immune ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell
Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Danaher Logo

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays